BBLG (Bone Biologics) Cyclically Adjusted Book per Share: $-3,110.82 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBLG Bone Biologics Corp BBLG
30 GF Score
Price $1.07
View Full Analysis

What is Bone Biologics Cyclically Adjusted Book per Share?

Bone Biologics BBLG -0.93% 30 Cyclically Adjusted Book per Share is $-3,110.82 as of Mar. 2026. GuruFocus rates BBLG with a GF Score™ of 30/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Bone Biologics's adjusted book value per share for the three months ended in Mar. 2026 was $2.602. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-3,110.82 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-25), Bone Biologics's current stock price is $1.07. Bone Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-3,110.82. Bone Biologics's Cyclically Adjusted PB Ratio of today is .


Bone Biologics  (NAS:BBLG) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Bone Biologics Cyclically Adjusted Book per Share Related Terms


Bone Biologics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Bone Biologics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bone Biologics Cyclically Adjusted Book per Share Chart

Bone Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -3,527.52 -3,155.33

Bone Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,480.19 -3,420.14 -3,357.70 -3,155.33 -3,110.82

BBLG vs VRAX, PKTX, OGEN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Bone Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bone Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bone Biologics's Cyclically Adjusted PB Ratio falls into.


BBLG
30GF Score
Bone Biologics Corp BBLG
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bone Biologics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bone Biologics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.602/330.2130*330.2130
=2.602

Current CPI (Mar. 2026) = 330.2130.

Bone Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -5,316.000 241.018 -7,283.325
201609 -7,050.000 241.428 -9,642.633
201612 -8,364.000 241.432 -11,439.666
201703 -8,270.000 243.801 -11,201.191
201706 -10,250.000 244.955 -13,817.572
201709 -10,904.000 246.819 -14,588.190
201712 -8,396.000 246.524 -11,246.241
201803 -8,534.000 249.554 -11,292.296
201806 -9,456.000 251.989 -12,391.391
201809 -3,587.000 252.439 -4,692.120
201812 -1,228.286 251.233 -1,614.422
201903 -1,246.500 254.202 -1,619.226
201906 -1,356.875 256.143 -1,749.249
201909 -1,264.667 256.759 -1,626.465
201912 -1,318.667 256.974 -1,694.494
202003 -1,385.000 258.115 -1,771.865
202006 -1,427.222 257.797 -1,828.133
202009 -1,471.000 260.280 -1,866.234
202012 -1,521.333 260.474 -1,928.653
202103 -1,569.333 264.877 -1,956.433
202106 -1,624.000 271.696 -1,973.772
202109 -1,680.556 274.310 -2,023.045
202112 939.286 278.802 1,112.490
202203 862.714 287.504 990.871
202206 798.286 296.311 889.621
202209 628.857 296.808 699.633
202212 540.636 296.797 601.506
202303 231.000 301.836 252.717
202306 87.585 305.109 94.791
202309 58.354 307.789 62.605
202312 32.652 306.746 35.150
202403 21.746 312.332 22.991
202406 13.283 314.175 13.961
202409 10.865 315.301 11.379
202412 7.081 315.605 7.409
202503 5.341 319.799 5.515
202506 3.915 322.561 4.008
202509 3.352 324.800 3.408
202512 2.996 324.054 3.053
202603 2.602 330.213 2.602

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-3,110.82 mean?
Bone Biologics (BBLG) has a Cyclically Adjusted Book per Share of $-3,110.82 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Bone Biologics and its competitors.
Is Bone Biologics' Cyclically Adjusted Book per Share too high?
Bone Biologics' current Cyclically Adjusted Book per Share is $-3,110.82. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' Cyclically Adjusted Book per Share compare to VRAX and PKTX?
Bone Biologics' Cyclically Adjusted Book per Share of $-3,110.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Bone Biologics and its competitors. Bone Biologics's current Cyclically Adjusted Book per Share is $-3,110.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current Cyclically Adjusted Book per Share of $-3,110.82. The current Cyclically Adjusted Book per Share is $-3,110.82. Bone Biologics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Bone Biologics (BBLG), the current Cyclically Adjusted Book per Share is $-3,110.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bone Biologics Business Description

Address 2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score

Get the complete analysis for BBLG

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price